Is Ketorolac a Controlled Substance or Narcotic?

Ketorolac is not a controlled substance and not a narcotic. It is a nonsteroidal anti-inflammatory drug (NSAID) in the same broad family as ibuprofen and naproxen, though considerably more potent. The confusion is understandable: ketorolac is frequently given by injection in emergency rooms and hospitals, it can rival opioids in pain relief for certain conditions, and its brand name Toradol sounds more like a heavy-duty painkiller than a relative of Advil. But it carries no DEA scheduling, requires no special prescribing license, and produces none of the euphoria, physical dependence, or respiratory depression that define narcotics.

Why People Think Ketorolac Is a Narcotic

Most NSAIDs come as pills you grab off a pharmacy shelf. Ketorolac, by contrast, is most commonly encountered as an intramuscular or intravenous injection administered in hospitals and emergency departments. That clinical setting alone creates an association with stronger, controlled medications. When a nurse gives you a shot for severe pain and the pain actually recedes quickly, the assumption that you just received something “stronger than a regular painkiller” is natural.

The potency doesn’t help the perception problem. Ketorolac is one of the few NSAIDs powerful enough to stand up against opioids in head-to-head comparisons for acute pain. A systematic review and meta-analysis of emergency department studies found that ketorolac provided comparable pain relief to opioids for conditions including headache, kidney stones, musculoskeletal injuries, and gallbladder pain.¹ That kind of performance sets it apart from most over-the-counter anti-inflammatories, but the mechanism behind it is still prostaglandin inhibition, the same basic pathway that ibuprofen uses. There is nothing opioid-like about how ketorolac works in the brain.

How Ketorolac Actually Works

All NSAIDs block enzymes called cyclooxygenases (COX-1 and COX-2), which your body uses to produce prostaglandins. Prostaglandins are chemical messengers that promote inflammation, sensitize nerve endings to pain, and raise body temperature. By shutting down prostaglandin production, ketorolac reduces swelling and lowers pain signaling at the source of the injury rather than dulling your brain’s perception of pain the way opioids do.

This distinction matters beyond pharmacology class. Because ketorolac doesn’t act on opioid receptors, it doesn’t cause sedation, doesn’t slow breathing, doesn’t produce a “high,” and doesn’t lead to the tolerance and withdrawal cycle that makes opioids so dangerous with repeated use. You won’t develop a craving for ketorolac, and stopping it abruptly won’t trigger withdrawal symptoms. Those characteristics are exactly why it is not scheduled as a controlled substance by the DEA or any equivalent agency.

Pain Relief That Matches Opioids

The reason ketorolac gets so much clinical attention is that, for many types of acute pain, it works about as well as morphine or other opioids. The emergency medicine meta-analysis mentioned earlier found no superiority of opioids over ketorolac for several common painful conditions seen in the ER.¹ A separate systematic review looking at non-narcotic analgesics for dental pain after root canal procedures found they significantly outperformed placebo at every time point measured, from immediately after the procedure through 24 hours later.²

These findings carry real-world weight. In the middle of an opioid crisis, having a non-addictive injectable that can match morphine for kidney stones or broken bones is a significant clinical tool. It’s also why ketorolac sometimes gets lumped in with “the strong stuff” in patients’ minds, even though its mechanism is entirely different.

The Opioid-Sparing Role

Even when ketorolac isn’t used alone, it frequently shows up alongside opioids to reduce how much of them a patient needs. This “opioid-sparing” effect is one of the drug’s most valuable properties in modern pain management. In a randomized, double-blinded trial of patients undergoing minimally invasive spinal fusion surgery, those who received ketorolac used significantly less opioid medication over 48 hours postoperatively and had shorter hospital stays, all while reporting similar pain scores to the placebo group.³

An earlier study found a similar pattern in women undergoing diagnostic laparoscopy: intravenous ketorolac given during the operation significantly reduced the amount of fentanyl needed afterward and lowered pain scores.⁴ That same study noted the effect didn’t hold for tubal ligation, a reminder that opioid-sparing benefits can vary by procedure. Still, across many surgical settings, adding ketorolac to the pain regimen means patients can take fewer opioid pills, face less nausea and constipation, and leave the hospital sooner.

The Five-Day Limit and Why It Exists

If ketorolac is so effective and non-addictive, why isn’t it prescribed more freely? The answer lies in its side-effect profile at higher doses and longer durations. Ketorolac is approved only for short-term management of moderately severe acute pain, and the FDA-labeled maximum duration is five days regardless of route (injection, oral tablet, or nasal spray). A review of its safety profile found that the risk of serious adverse events climbs with high doses and with therapy lasting beyond five days, especially in older adults.⁵

That five-day ceiling is considerably stricter than what most NSAIDs carry. Ibuprofen and naproxen can be taken for weeks or months under medical supervision, but ketorolac’s potency comes with amplified risks to the stomach, kidneys, and blood clotting system when used beyond the short window. This strict limit is another reason some patients assume ketorolac must be something more dangerous than a typical anti-inflammatory. It is more dangerous in some ways, but those dangers are NSAID-class dangers pushed to their extreme, not narcotic-class dangers.

Gastrointestinal Risks

The most concerning safety signal with ketorolac involves the gastrointestinal tract. A large epidemiological study found that ketorolac carried the highest risk of hospitalization for upper GI bleeding among all NSAIDs examined, roughly five times the risk of other NSAIDs as a group.⁶ That elevated risk held regardless of whether ketorolac was given by injection or taken orally, and it appeared within the first week of treatment.

This doesn’t mean everyone who gets a single Toradol shot in the ER is at high risk. The GI danger increases with repeated doses, longer treatment courses, and in patients who already have risk factors like a history of ulcers, concurrent use of blood thinners, or advanced age. After GI cancer surgery, researchers have noted that ketorolac’s side-effect profile includes the potential for GI tract bleeding and perforation, which is why prophylactic ulcer protection is sometimes used alongside it in surgical settings.⁷ For a one-time ER injection in a young, healthy person, the absolute risk is small. For repeated dosing in someone over 65 with a sensitive stomach, the calculus changes quickly.

Kidney Concerns

Like all NSAIDs, ketorolac can impair kidney function by blocking the prostaglandins that help maintain blood flow to the kidneys. In most healthy, well-hydrated people, this is a minor and reversible effect. But case reports have documented acute kidney failure and dangerous spikes in potassium in patients who had pre-existing conditions making their kidneys vulnerable, such as dehydration, heart failure, or existing kidney disease.⁸

The underlying issue is the same one that exists with ibuprofen or naproxen, just amplified by ketorolac’s potency and the clinical settings where it tends to be used. Patients receiving ketorolac are often postoperative, possibly dehydrated from fasting before surgery, and sometimes on other medications that also stress the kidneys. The combination is what creates trouble, not ketorolac acting in some unique, narcotic-like way. Clinicians generally check kidney function before giving ketorolac and avoid it entirely in patients with significant renal impairment.

Effects on Bleeding and Platelets

Ketorolac inhibits platelet function, which is worth knowing because it can prolong bleeding time. In a study of healthy volunteers, ketorolac significantly prolonged bleeding time compared to baseline measurements, though it did not significantly inhibit platelet aggregation in response to a standard laboratory stimulus.⁹ A separate study found a similar pattern: ketorolac prolonged bleeding time and inhibited platelet thromboxane production, though the bleeding time values remained within the normal range for most subjects.¹⁰

For someone without a bleeding disorder undergoing a routine procedure, this is unlikely to cause problems. But in patients with hemostatic defects, those taking blood thinners, or after surgeries where even a small increase in bleeding could be dangerous, ketorolac’s antiplatelet effect becomes a real consideration. Surgeons sometimes weigh this risk against the opioid-sparing benefit, and in many cases the trade-off favors ketorolac, but not universally.

Nasal Spray and Other Routes of Delivery

While ketorolac is best known as an injection, it also comes in oral tablets and an intranasal spray (brand name Sprix). The nasal formulation has gained interest because it offers a needle-free option that still bypasses the GI tract to some degree, delivering the drug through the nasal lining and into the bloodstream relatively quickly.

In a randomized trial of postoperative pain, intranasal ketorolac provided significantly better pain relief than placebo, with measurable improvement within 20 minutes of the first dose, and cut morphine use over 48 hours by about a quarter.¹¹ Adverse events were similar between the drug and placebo groups, though nasal irritation and a burning sensation in the nose were more common with ketorolac, as you’d expect from spraying an anti-inflammatory up your nose.

A systematic review of intranasal ketorolac across both adult and pediatric populations found that it provided comparable pain relief to opioids in several settings. For children with migraines, intranasal ketorolac worked about as well as the intravenous form, offering a non-invasive alternative. For kidney stones in the ER, it provided relief comparable to intravenous ketorolac and fentanyl.¹² The nasal spray is particularly appealing for patients who can’t take oral medication due to nausea or who want to avoid injections. A dental pain study also confirmed intranasal ketorolac as a practical non-narcotic alternative for clinicians looking for another tool in their pain management kit.¹³

Cost and Practical Advantages Over Morphine

Beyond the clinical benefits, ketorolac has a cost argument in its favor. A randomized controlled trial comparing intravenous ketorolac to intravenous morphine for limb injuries in an emergency department found ketorolac to be the more cost-effective option, with researchers describing it as the “dominant strategy,” meaning it was both cheaper and at least equally effective.¹⁴

There’s a logistical angle too. Because ketorolac isn’t a controlled substance, it doesn’t require the same documentation, locked storage, dual-verification, and regulatory paperwork that opioids demand in hospitals and pharmacies. A nurse can administer ketorolac without the witnessing and waste-disposal protocols required for morphine. In a busy emergency department, that difference in administrative burden adds up. It also means that when you leave the hospital with a ketorolac prescription, your pharmacist fills it like any other non-controlled medication, without the restrictions and stigma sometimes associated with opioid prescriptions.

Ketorolac in Veterinary Medicine

Ketorolac isn’t used only in humans. Veterinary medicine has explored it as a postoperative painkiller for dogs, and the results are interesting. In a study comparing ketorolac to two other analgesics after abdominal or shoulder surgery in dogs, ketorolac consistently received the highest pain-relief scores from evaluators. Dogs receiving ketorolac after abdominal surgery scored an average of 3.4 out of 4 for analgesic efficacy, compared to 2.7 for flunixin (another NSAID) and 1.6 for butorphanol (an opioid). After shoulder surgery, ketorolac scored 3.5, while butorphanol performed so poorly that researchers replaced it with a different opioid partway through the trial.¹⁵

The fact that ketorolac outperformed opioids in dogs after surgery mirrors what’s been found in human medicine: for certain acute pain scenarios, this NSAID can hold its own against or surpass traditional narcotic painkillers. Veterinary use remains more limited than in humans, partly because the same GI and renal risks apply to animals, but it illustrates how versatile the drug is across species.

Who Should Avoid Ketorolac

Despite its advantages, ketorolac isn’t appropriate for everyone. The groups who should be especially cautious or avoid it entirely include:

Older adults: The risk of GI bleeding and kidney problems is significantly higher in the elderly, and many prescribing guidelines recommend reduced doses or avoidance altogether in patients over 65.
People with kidney disease: Even mild renal impairment can tip into acute failure when prostaglandin-mediated blood flow to the kidneys is disrupted.
People with a history of GI bleeding or ulcers: Ketorolac’s GI toxicity is the highest among commonly used NSAIDs, making it a poor choice for anyone with a vulnerable stomach lining.
Patients on blood thinners: The combination of anticoagulant therapy and ketorolac’s antiplatelet effects creates an elevated bleeding risk.
Anyone needing pain relief beyond five days: If your pain is chronic or expected to last more than a few days, ketorolac simply isn’t designed for that purpose. Longer-term NSAIDs or other strategies are more appropriate.

The five-day limit is the single most important practical takeaway. Ketorolac is a sprinter, not a marathon runner. It’s built for the acute window after surgery, an ER visit for a kidney stone, or a severe migraine, not for managing ongoing back pain or arthritis.

The Controlled Substance Question in Context

Controlled substance scheduling in the United States is based on a drug’s potential for abuse and dependence, balanced against its medical utility. Substances like morphine, oxycodone, and fentanyl are Schedule II because they carry high abuse potential. Benzodiazepines and certain sleep medications are Schedule IV. Ketorolac falls outside this system entirely because it has no meaningful abuse potential. Nobody takes ketorolac recreationally. It doesn’t produce euphoria, doesn’t alter consciousness in a pleasurable way, and doesn’t create the neurochemical reward loop that drives addiction.

That said, the absence of controlled substance status doesn’t mean ketorolac is casual or harmless. The strict five-day limit, the injectable delivery, and the serious GI and renal risks make it a drug that demands respect and careful prescribing. It occupies an unusual space in pain medicine: not dangerous in the way narcotics are dangerous, but not as forgiving as most people assume non-narcotic painkillers to be. The risk profile is real, it’s just a completely different kind of risk from what makes opioids so problematic.